SGIOF
Shionogi & Co., Ltd.
Set alert
20.85 USD 0.00 0.00%
20.85 Day range 20.85
15.21 52-week range 26.00
- YTD
- +37.08%
- 1 year
- +15.13%
- Open
- 20.85
- Prev close
- 20.85
- Mkt cap
- 17.75B
- Vol
- 100
- Avg vol
- 32
- EPS
- 1.80
- P/E
- 11.58
More statistics
- Low
- 20.85
- High
- 20.85
- Earnings
- Oct 29, 2026
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.2493.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.2493 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.2861 | 0.706 | +0.42 | +146.77% |
| May 12, 2026 | Mar 31, 2026 | 0.3023 | 0.3474 | +0.05 | +14.92% |
| Jan 29, 2026 | Dec 31, 2025 | 0.384 | 0.56 | +0.18 | +45.83% |
| Oct 27, 2025 | Sep 30, 2025 | 0.3249 | 0.3509 | +0.03 | +8.00% |
| Jul 28, 2025 | Jun 30, 2025 | 0.2844 | 0.3216 | +0.04 | +13.08% |
News
- Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Shares Down 7.1% – Here’s What Happened
- Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
- Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
- Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
- New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
- Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
- Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
- Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
- Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
- Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Your note
Sign in to keep a note on SGIOF — it syncs with the Stock Master app.